GLP-1 drug shows little benefit for people with Parkinson’s disease, trial finds

by thinkia.org.in
0 comment


Credit: Unsplash/CC0 Public Domain

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s, finds a new study led by UCL researchers.

For their research, published in The Lancet, the team designed a randomized controlled Phase II trial to definitively determine whether exenatide use was associated with any benefit in people with Parkinson’s and if it led to a slower rate of progression of the illness, after smaller studies had suggested the drug may be helpful. The study is the world’s largest and longest trial of exenatide in people with Parkinson’s disease.

A total of 194 people with Parkinson’s disease participated in the trial across six research hospitals in the UK, including in London, Oxford, Plymouth, Salford and Edinburgh. They either used exenatide injections on a weekly basis, or a visually identical placebo.

The trial ran for 96 weeks and was double blind, meaning that neither the participants nor researchers knew who was receiving the real treatment or placebo.

At the end of the study period, the researchers found that there was no advantage at any point over the course of 96 weeks in the group using exenatide. And no benefits were shown in the objective examination of patients’ movements, their own reports of symptom severity, or imaging findings.

Lead author, Professor Thomas Foltynie (UCL Queen Square Institute of Neurology) said, “The results of this trial have been eagerly anticipated and the negative results will be a major disappointment to patients affected by Parkinson’s disease and the Parkinson’s disease research community.”

GLP-1 drugs—such as semaglutide (Wegovy) and Ozempic—have become increasingly popular over recent years and there has been an enormous interest in their potential health benefits.

For example, semaglutide (Wegovy) can be used as a treatment for type 2 diabetes alongside being a licensed weight loss drug.

Meanwhile, older members of the drug class—such as exenatide and lixisenatide—have also been shown to be capable of penetrating into the brain and previous small trials have suggested potential benefits to people with Parkinson’s disease.

Professor Foltynie added, “It is not yet clear whether there may be a subgroup of people with Parkinson’s disease who may get benefit from the use of exenatide. We will continue to scrutinize the data to see whether abnormal blood test results such as having ‘pre-diabetes’ might predict a better response to exenatide, and whether there were more of these people in the earlier, smaller trials in which we found positive overall effects.”

The trial took place at the UCL Queen Square Institute of Neurology and the UCLH National Hospital for Neurology and Neurosurgery.

There was a high level of participant retention throughout the trial and the research team have confirmed high levels of compliance with the medication by the use of blood tests checking the levels of exenatide, so there can be a high level of confidence in the results.

More information:
Exenatide once a week versus placebo as a potential disease modifying treatment for people with Parkinson’s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial, The Lancet (2025). DOI: 10.1016/S0140-6736(24)02808-3

Citation:
GLP-1 drug shows little benefit for people with Parkinson’s disease, trial finds (2025, February 4)
retrieved 5 February 2025
from https://medicalxpress.com/news/2025-02-glp-drug-benefit-people-parkinson.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



You may also like

Thinkia is a professional platform where we provide informative content like current world news, all types of educational content, health awareness, food awareness, travel awareness, ideas and tips. We hope you like all the content provided by us.

Editors' Picks

Latest Posts

Copyright © 2024 | Thinkia | All Right Reserved